Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.OQ)

SGYP.OQ on NASDAQ Stock Exchange Global Select Market

1.69USD
21 Sep 2018
Change (% chg)

-- (--)
Prev Close
$1.69
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
662,961
52-wk High
$3.57
52-wk Low
$1.42

Latest Key Developments (Source: Significant Developments)

Synergy Pharmaceuticals Announces Amendment To CRG Debt Agreement
Wednesday, 13 Jun 2018 07:30am EDT 

June 13 (Reuters) - Synergy Pharmaceuticals Inc ::SYNERGY PHARMACEUTICALS ANNOUNCES AMENDMENT TO CRG DEBT AGREEMENT.SYNERGY PHARMACEUTICALS INC - HAS ABILITY TO ACCESS UP TO $100 MILLION IN 2018 IN THREE TRANCHES UNDER AMENDED TERM LOAN AGREEMENT.SYNERGY PHARMACEUTICALS - RECEIVED A WAIVER TO EXTEND DRAW DOWN DATE OF SECOND BORROWING UNDER ITS TERM LOAN AGREEMENT WITH CRG LP TO AUG 29, 2018.SYNERGY PHARMACEUTICALS- AMENDED TERM LOAN AGREEMENT PROVIDES FOR FUTURE POTENTIAL BORROWINGS OF $25 MILLION & $25 MILLION ON/BEFORE AUG 29 & SEPT 30, 2018.SYNERGY PHARMACEUTICALS INC - AMENDED TERM LOAN AGREEMENT PROVIDES FOR FUTURE POTENTIAL BORROWINGS OF $50 MILLION ON OR BEFORE DECEMBER 31, 2018.  Full Article

Synergy Pharmaceuticals Qtrly Loss Per Share ‍$0.16
Thursday, 1 Mar 2018 04:20pm EST 

March 1 (Reuters) - Synergy Pharmaceuticals Inc ::SYNERGY PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS UPDATE.QTRLY LOSS PER SHARE ‍$0.16.Q4 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.  Full Article

Cipher Pharmaceuticals Acquires Exclusive Canadian Rights To FDA-Approved Trulance® From Synergy Pharma
Wednesday, 28 Feb 2018 07:00am EST 

Feb 28 (Reuters) - Cipher Pharmaceuticals Inc ::CIPHER PHARMACEUTICALS ACQUIRES EXCLUSIVE CANADIAN RIGHTS TO FDA-APPROVED TRULANCE® FROM SYNERGY PHARMACEUTICALS.CIPHER PHARMACEUTICALS INC - ‍UNDER TERMS OF LICENSING AGREEMENT, SYNERGY WILL RECEIVE AN UPFRONT PAYMENT OF US$5.0 MILLION​.CIPHER - ‍UNDER TERMS OF LICENSING AGREEMENT, SYNERGY ELIGIBLE FOR ADDITIONAL MILESTONE PAYMENT, & ROYALTIES FROM PRODUCT SALES IN CANADA​.CIPHER PHARMACEUTICALS INC - ‍AGREEMENT PROVIDES THAT SYNERGY WILL BE RESPONSIBLE FOR MANUFACTURING AND SUPPLYING FINISHED PRODUCT TO CO.  Full Article

Paulson & Co Dissolves Share Stake In Sprint, Cuts In Synergy Pharmaceuticals ‍​
Wednesday, 14 Feb 2018 05:40pm EST 

Feb 14 (Reuters) - PAULSON & CO ::PAULSON & CO DISSOLVES SHARE STAKE IN SPRINT ‍​.PAULSON & CO CUTS SHARE STAKE IN SYNERGY PHARMACEUTICALS TO 4 MILLION SHARES FROM 24.1 MILLION SHARES - SEC FILING.PAULSON & CO - CHANGE IN HOLDINGS ARE AS OF DEC 31, 2017 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF SEPT 30, 2017‍​.  Full Article

Synergy Pharma Meets Cash Balance Requirement
Thursday, 1 Feb 2018 08:00am EST 

Feb 1 (Reuters) - Synergy Pharmaceuticals Inc ::SYNERGY PHARMACEUTICALS SAYS HAS MET CASH BALANCE REQUIREMENT TO ACCESS ADDITIONAL CAPITAL UNDER TERM LOAN AGREEMENT DATED SEPT 1, 2017.  Full Article

CVI Investments reports a 7.9 pct passive stake in Synergy Pharmaceuticals as of Nov 13, 2017
Wednesday, 22 Nov 2017 05:00pm EST 

Nov 22 (Reuters) - Synergy Pharmaceuticals Inc :CVI Investments Inc reports a 7.9 percent passive stake in Synergy Pharmaceuticals Inc as of November 13, 2017 - SEC Filing‍​.  Full Article

Synergy Pharma announces pricing of offering of common stock and warrants
Monday, 13 Nov 2017 09:27am EST 

Nov 13 (Reuters) - Synergy Pharmaceuticals Inc :Synergy Pharmaceuticals announces pricing of offering of common stock and warrants.Synergy Pharmaceuticals - ‍pricing of offering of 21.7 million shares with accompanying warrants at combined price to public of $2.58/share and warrant​.  Full Article

Synergy Pharmaceuticals posts Q3 loss per share $0.22
Thursday, 9 Nov 2017 04:00pm EST 

Nov 9 (Reuters) - Synergy Pharmaceuticals Inc :Synergy Pharmaceuticals reports third quarter 2017 financial results and business update.Q3 loss per share $0.22.Q3 sales $5.0 million versus I/B/E/S view $4.5 million.Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Synergy Pharmaceuticals Inc - ‍cash and cash equivalents were about $117.8 million at end of quarter​.  Full Article

Synergy Pharmaceuticals secures $300 mln debt financing
Tuesday, 5 Sep 2017 08:30am EDT 

Sept 5 (Reuters) - Synergy Pharmaceuticals Inc :Synergy Pharmaceuticals secures $300 million debt financing.Synergy Pharmaceuticals- financing structure provides access to capital for support of commercialization of TRULANCE, funds current plans through 2019​.  Full Article

Synergy Pharma Q2 sales $2.3 million
Wednesday, 9 Aug 2017 04:30pm EDT 

Aug 9 (Reuters) - Synergy Pharmaceuticals Inc ::Synergy Pharmaceuticals reports second quarter 2017 financial results and business update.Q2 sales $2.3 million versus I/B/E/S view $2 million.Synergy Pharmaceuticals Inc - ‍FDA has accepted for review SNDA for Trulance for treatment of adults with IBS-C​.Synergy Pharmaceuticals Inc - ‍PDUFA date for Trulance is January 24, 2018​.Synergy Pharmaceuticals Inc qtrly net loss per common share $0.23.Q2 earnings per share view $-0.25, revenue view $2.0 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Synergy Pharmaceuticals Reports Q1 Loss Per Share $0.15

* SYNERGY PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE